EUVIMED · CrossrefJournal
Therapeutic Advances in Hematology
ISSN 2040-6207 · SAGE Publications
Latest articles
The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated patients with myelofibrosis: A prospective, multicenter, real-world study
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: A two-year living systematic review update
Effectiveness of recombinant factor IX Fc prophylaxis for the treatment of haemophilia B: A systematic review of real-world evidence
Outcomes of haploidentical versus matched related donor allogeneic stem cell transplantation in patients with myelodysplastic syndromes: A single-center retrospective cohort study
Acquired von Willebrand syndrome and chronic lymphocytic leukaemia/small lymphocytic lymphoma: Report of two cases and systematic review of the literature
Stanozolol plus avatrombopag for chemoradiotherapy-associated secondary aplastic anemia: A single-center retrospective cohort study
Comparable transplant outcomes with a decitabine-based reduced-toxicity regimen versus modified BUCY in older or frail MDS patients: A retrospective analysis of real-world practice
Real-world acute myeloid leukemia outcomes during a decade of molecular diagnostic expansion and azacitidine plus venetoclax adoption in Thailand: A single-center implementation cohort
Identification of novel UBE2E3::PDE1A and CTC1::MEF2C fusion transcripts in acute myeloid leukemia
Hypoplastic acute myeloid leukemia with aberrant lymphoid antigen expression and EWSR1::FEV fusion: A rare case report and literature review
Plain language summary: How safe and effective is long-term treatment with intravenous plasminogen concentrate for people with type 1 plasminogen deficiency?
Real-world US Experience with Voxelotor for Sickle Cell Disease: A Plain Language Summary of the RETRO and PROSPECT studies
Romiplostim during pregnancy in refractory primary immune thrombocytopenia: Literature review and case series
Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy
Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review
Isolated del(5q) with myeloproliferative driver mutations: A systematic review of published cases and clinical implications
Immune and cytokine landscape differs between cytopenic and proliferative phenotypes in primary myelofibrosis
Hetrombopag for enhancement of platelet engraftment after allogeneic hematopoietic stem cell transplantation: A single-center experience
Prevalence and factors associated with anemia among people living with HIV taking dolutegravir-based antiretroviral therapy at debre markos compressive specialized hospital, debre markos, northwest Ethiopia, 2024: A cross-sectional study
Assessing the value of fibro scan in the detection of liver fibrosis among patients with sickle cell disease– a single center study
Hypo-fractionated radiotherapy combined with PD-1 inhibitor for relapsed/refractory B-cell lymphoma after failure to CD19 CAR-T therapy
High-altitude polycythemia: State-of-the-art review
The combination of alternating reduced-dose blinatumomab and hyper-CVAD as consolidation therapy in patients with newly-diagnosed adult B-cell acute lymphoblastic leukemia
Treatment preferences of people with hemophilia and caregivers: a plain language summary
A plain language summary of the BASIS study looking at people living with severe hemophilia A or B with inhibitors and being treated with marstacimab
Plain language summary: What have research studies shown about plasma-derived human factor X concentrate treatment for people living with hereditary factor X deficiency?
Final data from the German AHEAD study: effectiveness and safety of octocog alfa and rurioctocog alfa pegol for hemophilia A in a real-world setting
Effect of marstacimab in young people living with severe hemophilia A or moderate to severe hemophilia B without inhibitors: A plain language summary from the BASIS study
Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary
Marstacimab for People with Severe Hemophilia A or Moderate to Severe Hemophilia B Without Inhibitors: A Plain Language Summary of Publication of the BASIS Study
EUVIMED